21665-58-7

Upstream product

• 110-91-8 morpholine 
• 2272-24-4 (4,6-dichloro-[1,3,5]triazin-2-yl)-p-tolyl-amine 
• 106-49-0 p-toluidine 
• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 

Downstream Products

• 21665-60-1 (4-morpholin-4-yl-6-piperazin-1-yl-[1,3,5]triazin-2-yl)-p-tolyl-amine 
• 1393922-26-3 N-(2-aminoethyl)-N'-(4-methylphenyl)-6-(morpholin-4-yl)-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

PIKFYVE INHIBITORS

The present application provides, inter alia, a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, a

Design and development of novel thiazolidin-4-one-1,3,5-triazine derivatives as neuro-protective agent against cerebral ischemia–reperfusion injury in mice via attenuation of NF-?B

The present study enumerates the discovery and development of novel thiazolidin-4-one-1,3,5-triazine as neuro-protective agent against cerebral ischemia–reperfusion injury in mice. These compounds showed significant inhibition of NF-?B transcriptional activity in LPS-stimulated RAW264.7 cells, displaying compound 8k as most potent inhibitor among the tested derivative. The compound 8k was further studied in in vivo middle cerebral artery occlusion (MCAO) mice model for neuro-protective action. Results suggest that compound 8k causes attenuation of inflammation (TNF-α, IL-β, and IL-6), oxidative stress (SOD, GSH, and MDA), and apoptosis (Bcl-2, Bax, and cleaved caspase-3) in MCAO mice in concentration-dependent manner. Collectively, our results documented that compound 8k pre-treatment protects cerebral I/R. This novel lead scaffold may be helpful for investigation of new neuro-protective agent by inactivation of NF-?B.

Design and Development of Novel 4-(4-(1H-Tetrazol-5-yl)-1H-pyrazol-1-yl)-6-morpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine as Cardiotonic Agent via Inhibition of PDE3

The classical phosphodiesterase 3A (PDE3A) inhibitors provide relaxation of the vasculature system via increasing the cellular level of cyclic adenosine monophosphate (cAMP) and proved to be useful in the management of congestive heart failure. Consequent

Synthesis and antimalarial-activity evaluation of tetraoxane-triazine hybrids and spiro[piperidine-4,3′-tetraoxanes]

A series of tetraoxane-triazine hybrids and spiro[piperidine-4,3′- tetraoxanes] have been synthesized, and all the compounds were screened for in vitro antimalarial activity against chloroquine-sensitive (D6) and chloroquine-resistant (W2) strains of Plas

Synthesis and bioevaluation of hybrid 4-aminoquinoline triazines as a new class of antimalarial agents

The emergence and rapid spread of chloroquine resistant strains of Plasmodium falciparum has dramatically reduced the chemotherapeutic options. Towards this goal, a series of new class of hybrid 4-aminoquinoline triazines were synthesized and screened aga